Omalizumab for the Treatment of Patients with Asthma BPCO Overlap Syndrome : our experience

. The purpose of this study is to conduct an exploratory study on the effect of Omalizumab on COPD patients with elevated specific perennial IgE.Outcomes include to determine wheter Omalizumab use:reduce exacerbations in COPD patients; modified CAT score, Forced expiratory volume at one second (FEV 1), GOLD category.Whe are included patients with COPD on the GOLD criteria and with elevated IgE for perennial allergens. Pulmonary function was evaluated and fev1 determined. We enrolled seven patients ( 3women), smokers, with perennial allergen sensitivity (dermatophagoides) and COPD. Mean age 61,14 ± 22,81 , FEV 1( liters) 1,23 ± 0,52 Fev 1% 52,81±15,61, exacerbatione in the past years 2,85±o,69  CAT score 26,85± 7,58, all in GOLD gategory D, total IgE 361,25±265 .Omalizumab therapy was starded ,in addition to usual COPD therapy.Monthly dosing of omalizumab was 578,57±317,35. After eighteen months of treatment the results are: Fev1 % 58,6±15,08 p=0.12 ns,CAT score 15,43 p=0.00; exacerbations 0,42 p=0.00. None of the patients resulted in D category. Conclusions : the treatment with omalizumab is effective in COPD patients with sensitivity to perennial allergens, to reduce number of exacerbations , to improve control of symptoms,to reduce drugs consumption